On April 10, 2014, Aptose Biosciences completed its public offering of 50,000,000 common shares at C$0.50 per share, for aggregate gross proceeds of C$25 million. The offering was sold to a syndicate of underwriters led by RBC Capital Markets, and including Roth Capital Partners and Cormark Securities Inc. Aptose Biosciences granted the underwriters an over-allotment option to purchase up to 7,500,000 additional common shares at the offering price.


The net proceeds from the offering will be used to fund Aptose Biosciences' manufacturing program of LOR-253, support ongoing research and development programs, fund potential single agent expansion and drug combination Phase 2 trials in both Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS) patients (depending on Phase 1b clinical trial of LOR-253 results), and for general and corporate working capital purposes.



Aptose Biosciences, headquartered in Toronto, Ontario, is a biopharmaceutical company. It focuses on the discovery, research and development of anti-cancer therapies.


McCarthy Tétrault LLP represented Aptose Biosciences, the issuer, with a team led by Charles-Antoine Soulière, and including  Myreille Gilbert and Jacob Stone (securities); and Ryan Rabinovitch (tax).